Table I.
Baseline demographic and clinicopathological characteristics of the patients (n=120).
| Characteristics | Child-Pugh B, no. (%) (n=20) | Child-Pugh A, no. (%) n=100 (100%) |
|---|---|---|
| Age, years | ||
| Median (range) | 56 (28–73) | 61 (19–80) |
| Gender | ||
| Male | 14 (70.0) | 73 (73.0) |
| Female | 6 (30.0) | 27 (27.0) |
| ECOG PS | ||
| 0 or 1 | 16 (80.0) | 87 (87.0) |
| 2 or 3 | 4 (20.0) | 13 (13.0) |
| Coexisting liver disease | ||
| Hepatitis B | 2 (10.0) | 12 (12.0) |
| Hepatitis C | 13 (65.0) | 27 (27.0) |
| Alcohol-related | 2 (10.0) | 13 (13.0) |
| Other/unknown | 3 (15.0) | 48 (48.0) |
| Extrahepatic spreada | 13 (65.0) | 51 (51.0) |
| Lung | 6 (30.0) | 20 (20.0) |
| Lymph nodes | 5 (25.0) | 10 (10.0) |
| Bone | 4 (20.0) | 18 (18.0) |
| Macroscopic vascular invasion | 8 (40.0) | 43 (43.0) |
| BCLC stage | ||
| B | 4 (20.0) | 18 (18.0) |
| C | 16 (80.0) | 82 (82.0) |
| Previous locoregional treatment | 7 (35.0) | 38 (38.0) |
| Child-Pugh class | ||
| A5 | 68 (68.0) | |
| A6 | 32 (32.0) | |
| B7 | 19 (95.0) | |
| B8 | 1 (05.0) | |
| Ascites | 13 (65.0) | 17 (17.0) |
| Biochemical analysis | ||
| Albumin, g/dl | ||
| Median (range) | 3.15 (2.2–4.0) | 3.90 (2.8–5.10) |
| TBIL, mg/dl | ||
| Median (range) | 1.9 (0.28–26.38) | 0.88 (0.24–2.42) |
| AFP, ng/ml | ||
| Median (range) | 1,030 (3.0–60,500) | 568.3 (0.9–60,500) |
| ALP, U/l | ||
| Median (range) | 181 (9.8–3,200) | 158 (55–805) |
a
Some patients had more than one site of metastasis. ECOG PS, Eastern Cooperative Oncology Group performance status; BCLC, Barcelona Clinic Liver Cancer; TBIL, total bilirubin; AFP, α-fetoprotein; ALP, alkaline phosphatase.